1
/
of
0
Cabxel (Cabazitaxel)
Cabxel (Cabazitaxel)
Regular price
₱45,000.00 PHP
Regular price
Sale price
₱45,000.00 PHP
Taxes included.
Quantity
Couldn't load pickup availability
Cabazitaxel (Cabxel) is an advanced antineoplastic chemotherapy agent designed for treating metastatic castration-resistant prostate cancer (mCRPC). This potent taxane derivative works by disrupting microtubule dynamics in cancer cells, effectively halting tumor progression in men who have previously been treated with docetaxel-containing regimens.
Indicated specifically for combination therapy with prednisone, Cabazitaxel represents a critical treatment option for patients experiencing docetaxel-resistant disease. It penetrates the blood-brain barrier more effectively than traditional taxanes, offering enhanced efficacy in aggressive, treatment-resistant malignancies.
Key clinical benefits include improved overall survival rates, extended progression-free survival, and demonstrable tumor response in heavily pretreated patient populations. Cabazitaxel has been shown to reduce the risk of death compared to mitoxantrone-based alternatives, making it the preferred second-line chemotherapeutic choice for advanced prostate cancer management.
Important safety considerations include absolute contraindication in patients with severe hepatic impairment, neutrophil counts below 1,500/mm³, or documented hypersensitivity to cabazitaxel or other taxane compounds. Patients with compromised performance status or significant comorbidities require careful clinical evaluation before initiating therapy.
Dosage administration must be strictly individualized and determined exclusively by qualified oncology physicians. This medication demands comprehensive medical consultation, baseline laboratory assessment, and ongoing monitoring throughout treatment. Potential adverse effects include myelosuppression, hypersensitivity reactions, and gastrointestinal complications, requiring vigilant clinical oversight.
Cabazitaxel is a prescription-only medication available through licensed pharmacy channels and must be dispensed under strict regulatory compliance. Patients should maintain open communication with their healthcare provider regarding efficacy, side effect management, and treatment continuation protocols.
Indicated specifically for combination therapy with prednisone, Cabazitaxel represents a critical treatment option for patients experiencing docetaxel-resistant disease. It penetrates the blood-brain barrier more effectively than traditional taxanes, offering enhanced efficacy in aggressive, treatment-resistant malignancies.
Key clinical benefits include improved overall survival rates, extended progression-free survival, and demonstrable tumor response in heavily pretreated patient populations. Cabazitaxel has been shown to reduce the risk of death compared to mitoxantrone-based alternatives, making it the preferred second-line chemotherapeutic choice for advanced prostate cancer management.
Important safety considerations include absolute contraindication in patients with severe hepatic impairment, neutrophil counts below 1,500/mm³, or documented hypersensitivity to cabazitaxel or other taxane compounds. Patients with compromised performance status or significant comorbidities require careful clinical evaluation before initiating therapy.
Dosage administration must be strictly individualized and determined exclusively by qualified oncology physicians. This medication demands comprehensive medical consultation, baseline laboratory assessment, and ongoing monitoring throughout treatment. Potential adverse effects include myelosuppression, hypersensitivity reactions, and gastrointestinal complications, requiring vigilant clinical oversight.
Cabazitaxel is a prescription-only medication available through licensed pharmacy channels and must be dispensed under strict regulatory compliance. Patients should maintain open communication with their healthcare provider regarding efficacy, side effect management, and treatment continuation protocols.